Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.
Type:
Application
Filed:
November 18, 2022
Publication date:
March 16, 2023
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.
Type:
Application
Filed:
July 21, 2022
Publication date:
February 9, 2023
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.
Type:
Grant
Filed:
October 4, 2017
Date of Patent:
November 1, 2022
Assignee:
ENGENEIC MOLECULAR DELIVERY PTY LTD
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: This disclosure relates generally to compositions and methods for treating cancer. The compositions comprise bacterially derived intact minicells or intact killed bacterial cells.
Type:
Application
Filed:
April 30, 2020
Publication date:
June 30, 2022
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
Type:
Grant
Filed:
January 28, 2018
Date of Patent:
June 14, 2022
Assignee:
EngeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, viral infections, including coronavirus infections.
Type:
Application
Filed:
September 20, 2021
Publication date:
April 14, 2022
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
Type:
Application
Filed:
March 25, 2021
Publication date:
July 15, 2021
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
Type:
Grant
Filed:
October 23, 2017
Date of Patent:
May 4, 2021
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
October 13, 2020
Assignee:
ENGENEIC MOLECULAR DELIVERY PTY LTD
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
Type:
Grant
Filed:
June 4, 2018
Date of Patent:
March 10, 2020
Assignee:
EnGeneIC Molecular Delivery Pty Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.
Type:
Application
Filed:
July 22, 2019
Publication date:
February 20, 2020
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
Type:
Grant
Filed:
July 28, 2017
Date of Patent:
December 10, 2019
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Type:
Grant
Filed:
August 11, 2017
Date of Patent:
October 1, 2019
Assignee:
ENGENEIC MOLECULAR DELIVERY PTY. LTD.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Grant
Filed:
October 10, 2018
Date of Patent:
August 20, 2019
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Application
Filed:
October 10, 2018
Publication date:
March 28, 2019
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MACDIARMID, Toby HULF
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Grant
Filed:
June 19, 2015
Date of Patent:
October 16, 2018
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
Type:
Grant
Filed:
April 17, 2013
Date of Patent:
September 18, 2018
Assignee:
EnGeneIC Molecular Delivery Pty. Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
Type:
Grant
Filed:
August 6, 2015
Date of Patent:
June 5, 2018
Assignee:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
Type:
Application
Filed:
January 12, 2018
Publication date:
May 17, 2018
Applicant:
EnGeneIC Molecular Delivery Pty Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid